Evidence map›Paper›PMID 37560093›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Internal Validation of Automated Visual Evaluation (AVE) on Smartphone Images for Cervical Cancer Screening in a Prospective Study in Zambia.

Liming Hu, Mulindi H Mwanahamuntu, Vikrant V Sahasrabuddhe, Caroline Barrett, Matthew P Horning, Ishan Shah, Zohreh Laverriere, Dipayan Banik, Ye Ji, Aaron Lunda Shibemba and 7 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Liming HuGlobal Health Labs, Inc, USA.
Mulindi H MwanahamuntuUniversity Teaching Hospital, Zambia.
Vikrant V SahasrabuddheNational Cancer Institute, NIH, USA.
Caroline BarrettClinton Health Access Initiative (CHAI), Inc, USA.
Matthew P HorningGlobal Health Labs, Inc, USA.
Ishan ShahGlobal Health Labs, Inc, USA.
Zohreh LaverriereGlobal Health Labs, Inc, USA.
Dipayan BanikGlobal Health Labs, Inc, USA.
Ye JiGlobal Health Labs, Inc, USA.
Aaron Lunda ShibembaUniversity Teaching Hospital, Zambia.
Samson ChiseleUniversity Teaching Hospital, Zambia.
Mukatimui Kalima MunalulaUniversity Teaching Hospital, Zambia.
Friday KaungaUniversity Teaching Hospital, Zambia.
Francis MusondaUniversity Teaching Hospital, Zambia.
Evans MalyanguUniversity Teaching Hospital, Zambia.
Karen Milch HariharanClinton Health Access Initiative (CHAI), Inc, USA.
Groesbeck P ParhamUniversity Teaching Hospital, Zambia.
University Teaching Hospital · ZMClinton Health Access Initiative · USNational Cancer Institute · USUniversity of North Carolina at Chapel Hill · US

Funding

Development, field testing and evaluation of the efficacy of a hand-held, portable and affordable thermo-coagulator to prevent cervical cancer in low- and middle-income countries -admin supplementUH3CA202721 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI BASU, PARTHA · 2018 to 2023
$3.2M
NCI NIH HHS UH3 CA202721
6 · The paper itself

Abstract

Objectives: Visual inspection with acetic acid (VIA) is a low-cost approach for cervical cancer screening used in most low- and middle-income countries (LMICs) but, similar to other visual tests like histopathology, is subjective and requires sustained training and quality assurance. We developed, trained, and validated an artificial-intelligence-based "Automated Visual Evaluation" (AVE) tool that can be adapted to run on smartphones to assess smartphone-captured images of the cervix and identify precancerous lesions, helping augment performance of VIA. Design: Prospective study. Setting: Eight public health facilities in Zambia. Participants: 8,204 women aged 25-55. Interventions: Cervical images captured on commonly used low-cost smartphone models were matched with key clinical information including human immunodeficiency virus (HIV) and human papillomavirus (HPV) status, plus histopathology analysis (where applicable), to develop and train an AVE algorithm and evaluate its performance for use as a primary screen and triage test for women who are HPV positive. Main outcome measures: Area under the receiver operating curve (AUC); sensitivity; specificity. Results: As a general population screening for cervical precancerous lesions, AVE identified cases of cervical precancerous and cancerous (CIN2+) lesions with high performance (AUC = 0.91, 95% confidence interval [CI] = 0.89 to 0.93), which translates to a sensitivity of 85% (95% CI = 81% to 90%) and specificity of 86% (95% CI = 84% to 88%) based on maximizing the Youden's index. This represents a considerable improvement over VIA, which a meta-analysis by the World Health Organization (WHO) estimates to have sensitivity of 66% and specificity of 87%. For women living with HIV, the AUC of AVE was 0.91 (95% CI = 0.88 to 0.93), and among those testing positive for high-risk HPV types, the AUC was 0.87 (95% CI = 0.83 to 0.91). Conclusions: These results demonstrate the feasibility of utilizing AVE on images captured using a commonly available smartphone by screening nurses and support our transition to clinical evaluation of AVE's sensitivity, specificity, feasibility, and acceptability across a broader range of settings. The performance of the algorithm as reported may be inflated, as biopsies were obtained only from study participants with visible aceto-white cervical lesions, which can lead to verification bias; and the images and data sets used for testing of the model, although "unseen" by the algorithm during training, were acquired from the same set of patients and devices, limiting the study to that of an internal validation of the AVE algorithm.

Identifiers

PMID37560093
PMCPMC10407974
OpenAlexW4385163594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.